HEALTH: EU AUTHORIZES FIRST RESPIRATORY VIRUS VACCINATION
Read Time:55 Second
According to GlaxoSmithKline, the Respiratory Syncytial Virus vaccine for individuals 60 and older has received approval from the European Commission, following the United States.
According to GSK’s chief scientific officer, Tony Wood, “this Arexvy authorization means eligible adults can receive the RSV vaccine for the first time.”
The medicine was just given U.S. approval, while the vaccination is the result of decades of research into how to shield susceptible individuals from the frequent ailment.
RSV typically only causes minor, cold-like symptoms, but it can be dangerous for young children, the elderly, those with weakened immune systems, and people with underlying medical issues.
In extreme situations, it may result in pneumonia and bronchiolitis, an inflammation of the lungs’ tiny airways.
According to analysts, the market may be worth more than $10 billion in the following ten years, and similar products from other manufacturers, such as Pfizer and Moderna, are anticipated to follow soon.
According to GSK, RSV is “a common, contagious respiratory virus that causes 20,000 in-hospital deaths in adults aged 60 and over in Europe each year.”
Happy
0 %
Sad
0 %
Excited
0 %
Sleepy
0 %
Angry
0 %
Surprise
0 %
0
0